Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Largent-Milnes TM, Brookshire SW, Skinner DP Jr, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca F, Hruby VJ, Vanderah TW.

J Pharmacol Exp Ther. 2013 Oct;347(1):7-19. doi: 10.1124/jpet.113.205245. Epub 2013 Jul 16.

2.

Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.

Br J Pharmacol. 2010 Nov;161(5):986-1001. doi: 10.1111/j.1476-5381.2010.00824.x.

3.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
4.

Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Giri AK, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F, Vanderah TW, Hruby VJ.

J Med Chem. 2015 Nov 12;58(21):8573-83. doi: 10.1021/acs.jmedchem.5b01170. Epub 2015 Oct 30.

PMID:
26465170
6.

[Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.

Riba P, Ben Y, Nguyen TM, Furst S, Schiller PW, Lee NM.

Curr Med Chem. 2002 Jan;9(1):31-9.

PMID:
11860345
7.

Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang ET, Malan TP Jr, Ossipov MH, Lai J, Porreca F.

J Neurosci. 2000 Sep 15;20(18):7074-9.

8.

Opioid and substance P receptor adaptations in the rat spinal cord following sub-chronic intrathecal treatment with morphine and naloxone.

Gouarderes C, Jhamandas K, Cridland R, Cros J, Quirion R, Zajac JM.

Neuroscience. 1993 Jun;54(3):799-807.

PMID:
7687333
9.

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.

Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K.

J Pain. 2008 Dec;9(12):1144-54. doi: 10.1016/j.jpain.2008.06.014. Epub 2008 Aug 16.

PMID:
18708300
10.

Inhibition by spinal mu- and delta-opioid agonists of afferent-evoked substance P release.

Kondo I, Marvizon JC, Song B, Salgado F, Codeluppi S, Hua XY, Yaksh TL.

J Neurosci. 2005 Apr 6;25(14):3651-60.

11.

In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.

Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ.

J Pharmacol Exp Ther. 2011 Mar;336(3):767-78. doi: 10.1124/jpet.110.172866. Epub 2010 Nov 30.

12.
13.

Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects.

Stone LS, German JP, Kitto KF, Fairbanks CA, Wilcox GL.

PLoS One. 2014 Oct 9;9(10):e109903. doi: 10.1371/journal.pone.0109903. eCollection 2014.

14.

Intrathecal atipamezole augments the antinociceptive effect of morphine in rats.

Lilius TO, Rauhala PV, Kambur O, Rossi SM, Väänänen AJ, Kalso EA.

Anesth Analg. 2012 Jun;114(6):1353-8. doi: 10.1213/ANE.0b013e31824c727d. Epub 2012 May 3.

PMID:
22556211
15.
16.

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians.

Pain Physician. 2012 Jul;15(3 Suppl):S67-116.

17.

Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.

Gallantine EL, Meert TF.

Basic Clin Pharmacol Toxicol. 2008 Nov;103(5):419-27. doi: 10.1111/j.1742-7843.2008.00306.x. Epub 2008 Aug 11.

18.

Peripherally-acting opioids.

Smith HS.

Pain Physician. 2008 Mar;11(2 Suppl):S121-32. Review.

19.
20.

Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, Zaveri NT.

J Pharmacol Exp Ther. 2009 Dec;331(3):954-64. doi: 10.1124/jpet.109.157446. Epub 2009 Sep 22.

Supplemental Content

Support Center